{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:07:29Z","timestamp":1772460449387,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Medicine Siriraj Hospital, Bangkok, Thailand","award":["R015932032"],"award-info":[{"award-number":["R015932032"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This study aimed to identify factors that significantly influence the pharmacokinetics of voriconazole in Thai adults with hematologic diseases, and to determine optimal voriconazole dosing regimens. Blood samples were collected at steady state in 65 patients (237 concentrations) who were taking voriconazole to prevent or treat invasive aspergillosis. The data were analyzed using a nonlinear mixed-effects modeling approach. Monte Carlo simulation was applied to optimize dosage regimens. Data were fitted with the one-compartment model with first-order absorption and elimination. The apparent oral clearance (CL\/F) was 3.43 L\/h, the apparent volume of distribution (V\/F) was 47.6 L, and the absorption rate constant (Ka) was fixed at 1.1 h\u22121. Albumin and omeprazole \u2265 40 mg\/day were found to significantly influence CL\/F. The simulation produced the following recommended maintenance doses of voriconazole: 50, 100, and 200 mg every 12 h for albumin levels of 1.5\u20133, 3.01\u20134, and 4.01\u20134.5 g\/dL, respectively, in patients who receive omeprazole \u2264 20 mg\/day. Patients who receive omeprazole \u2265 40 mg\/day and who have serum albumin level 1.5\u20133 and 3.01\u20134.5 g\/dL should receive voriconazole 50 and 100 mg, every 12 h, respectively. Albumin level and omeprazole dosage should be carefully considered when determining the appropriate dosage of voriconazole in Thai patients.<\/jats:p>","DOI":"10.3390\/antibiotics9090574","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:22:43Z","timestamp":1599132163000},"page":"574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases"],"prefix":"10.3390","volume":"9","author":[{"given":"Buddharat","family":"Khan-asa","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"},{"name":"Inpatient Pharmacy Department, Pharmacy Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baralee","family":"Punyawudho","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noppaket","family":"Singkham","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, University of Phayao, Phayao 56000, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyawat","family":"Chaivichacharn","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekapun","family":"Karoopongse","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preecha","family":"Montakantikul","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-4914","authenticated-orcid":false,"given":"Methee","family":"Chayakulkeeree","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","unstructured":"Pfizer (2020, February 24). Vfend\u00ae, Voriconazole, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021266s039,021267s050,021630s029lbl.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","article-title":"Practice guidelines for therapeutic drug monitoring of voriconazole: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Hamada","year":"2013","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: Assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40262-019-00735-7","article-title":"Voriconazole: A review of population pharmacokinetic analyses","volume":"58","author":"Shi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: Implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/FTD.0000000000000425","article-title":"Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients","volume":"39","author":"Li","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.02808-13","article-title":"Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis","volume":"58","author":"Liu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/bcp.13595","article-title":"Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients","volume":"84","author":"Lin","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cpt.1012","article-title":"Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults","volume":"104","author":"Mangal","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.clinthera.2019.04.027","article-title":"Model-based voriconazole dose optimization in Chinese adult patients with hematologic malignancies","volume":"41","author":"Liu","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kim, Y., Rhee, S.J., Park, W.B., Yu, K.S., Jang, I.J., and Lee, S. (2019). A Personalized CYP2C19 phenotype-guided dosing regimen of voriconazole using a population pharmacokinetic analysis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020227"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s13318-019-00556-w","article-title":"Population pharmacokinetics of voriconazole in Chinese patients with hematopoietic stem cell transplantation","volume":"44","author":"Chen","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00504-10","article-title":"Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients","volume":"54","author":"Han","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1248\/bpb.b14-00768","article-title":"Population pharmacokinetics in China: The dynamics of intravenous voriconazole in critically ill patients with pulmonary disease","volume":"38","author":"Chen","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/imj.14241","article-title":"Is there a role for proton pump inhibitor prophylaxis in haematology patients?","volume":"49","author":"Leitinger","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_27","first-page":"232","article-title":"Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients","volume":"98","author":"Chayakulkeeree","year":"2015","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nut.2017.04.011","article-title":"Assessment of the nutritional status of adult patients with acute myeloid leukemia during induction chemotherapy","volume":"41","author":"Deluche","year":"2017","journal-title":"Nutrition"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40780-016-0044-9","article-title":"A retrospective analysis of patient-specific factors on voriconazole clearance","volume":"2","author":"Dote","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_30","first-page":"85","article-title":"CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors","volume":"6","author":"Sukasem","year":"2013","journal-title":"Pharmgen. Pers. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10096-008-0543-1","article-title":"Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies","volume":"27","author":"Nomura","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/11538690-000000000-00000","article-title":"Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients","volume":"50","author":"Han","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/AAC.03641-14","article-title":"Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients","volume":"58","author":"Vanstraelen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.00429-09","article-title":"Voriconazole pharmacokinetics in liver transplant recipients","volume":"54","author":"Johnson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5414\/CP203345","article-title":"Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin","volume":"57","author":"Hirata","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","article-title":"Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole","volume":"49","author":"Qi","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2125.2003.02000.x","article-title":"Effect of omeprazole on the steady-state pharmacokinetics of voriconazole","volume":"56","author":"Wood","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0076-6879(96)72016-5","article-title":"Assays of omeprazole metabolism as a substrate probe for human CYP isoforms","volume":"272","author":"Birkett","year":"1996","journal-title":"Methods Enzymol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.1994.tb04310.x","article-title":"Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism","volume":"37","author":"Andersson","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern. Med. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","first-page":"S98","article-title":"Rapid high performance liquid chromatographic assay for determination of voriconazole concentration in human plasma","volume":"96","author":"Sangsiriwut","year":"2013","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:06:33Z","timestamp":1760177193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["antibiotics9090574"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9090574","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}